Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-...

Full description

Autores:
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13493
Acceso en línea:
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltext
http://hdl.handle.net/20.500.12010/13493
https://doi.org/10.1016/j.eclinm.2020.100459
Palabra clave:
tocilizumab
tocilizumab
anti-soluble IL-6 receptor
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Acceso restringido